Publication
Article
Author(s):
As many as 30% of your patients will experience treatment-resistant depression...
PUBLISHER'S NOTE
Estimates indicate as many as 30% of your patients will experience treatment-resistant depression (TRD), and that number may change as the definition of TRD is explored, challenged, and honed. As our understanding of depression deepens, so does the complexity of addressing cases that defy conventional therapeutic approaches—and ensuring that patients are receiving the correct diagnosis and a full complement of appropriate treatment. Thus, the landscape of TRD presents an evolving challenge for psychiatric clinicians. Recognizing the emerging issues in TRD is crucial for mental health professionals to better support their patients on the path to recovery.
With that in mind, this Special Report in this issue of Psychiatric Times explores TRD and provides insights to support you as you find ways to help your patients. Specifically, experts share their thoughts on the supportive role of psychotherapy as well as unique issues for your older patients. In addition to these thoughtful discussions in this print issue, you will find more information and discussion on our website—PsychiatricTimes.com.
As usual, this issue also shares insights into the other issues most pressing for practicing psychiatrists. We have gathered experts and research reviews on schizophrenia, neuropsychiatry, and psychosomatic disorders to bring you the latest information and clinical pearls.
We would be remiss if we did not note that November is a time of thanks, and as we share this issue of Psychiatric Times, we are thankful for you, our valued readers, who read and enjoy each issue cover to cover. Our goal is to continue to be the best-read psychiatric publication in the United States. As such, we encourage you to reach out to us. Please let us know if there is anything you would like to contribute and how we may best serve you by emailing PTEditor@mmhgroup.com.
Wishing you and yours a lovely Thanksgiving.
Mike Hennessy Jr
President and CEO, MJH Life Sciences®